These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 10584132

  • 1. [Alteration of radiation-induced hematotoxicity by amifostine (ethyol)].
    Momm F, Bechtold C, Fischer K, Tsekos A, Henke M.
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():2-5. PubMed ID: 10584132
    [Abstract] [Full Text] [Related]

  • 2. Alteration of radiation-induced hematotoxicity by amifostine.
    Momm F, Bechtold C, Rudat V, Strnad V, Tsekos A, Fischer K, Henke M.
    Int J Radiat Oncol Biol Phys; 2001 Nov 15; 51(4):947-51. PubMed ID: 11704315
    [Abstract] [Full Text] [Related]

  • 3. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
    Vacha P, Marx M, Engel A, Richter E, Feyerabend T.
    Strahlenther Onkol; 1999 Nov 15; 175 Suppl 4():18-22. PubMed ID: 10584135
    [Abstract] [Full Text] [Related]

  • 4. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S, Hoffmanns H.
    Strahlenther Onkol; 1999 Nov 15; 175 Suppl 4():30-3. PubMed ID: 10584138
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A, Kennedy T, Pellitteri P, Wood C, Christie D, Yumen O.
    Int J Radiat Oncol Biol Phys; 2007 Dec 01; 69(5):1361-8. PubMed ID: 17869022
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E, Martin L, Calais G, Tuchais C, Bourhis J, Rhein B, Feham N, Alphonsi M.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M, Rosenthal DI, Chalian AA, Lustig R, Hershock D, Miller L, Weinstein GS, Weber RS.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):72-7. PubMed ID: 15093901
    [Abstract] [Full Text] [Related]

  • 12. Moist skin care can diminish acute radiation-induced skin toxicity.
    Momm F, Weissenberger C, Bartelt S, Henke M.
    Strahlenther Onkol; 2003 Oct 01; 179(10):708-12. PubMed ID: 14566480
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R.
    Semin Oncol; 2004 Dec 01; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB.
    Cancer; 2009 Oct 01; 115(19):4514-23. PubMed ID: 19634161
    [Abstract] [Full Text] [Related]

  • 18. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
    Peters K, Mücke R, Hamann D, Ziegler PG, Fietkau R.
    Strahlenther Onkol; 1999 Nov 01; 175 Suppl 4():23-6. PubMed ID: 10584136
    [Abstract] [Full Text] [Related]

  • 19. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
    Jellema AP, Slotman BJ, Muller MJ, Leemans CR, Smeele LE, Hoekman K, Aaronson NK, Langendijk JA.
    Cancer; 2006 Aug 01; 107(3):544-53. PubMed ID: 16804929
    [Abstract] [Full Text] [Related]

  • 20. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial.
    Bardet E, Martin L, Calais G, Alfonsi M, Feham NE, Tuchais C, Boisselier P, Dessard-Diana B, Seng SH, Garaud P, Aupérin A, Bourhis J.
    J Clin Oncol; 2011 Jan 10; 29(2):127-33. PubMed ID: 21115863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.